•     Testimonials      •     Verdicts      •     Bios      •

Contact Us

Boston Scientific Taxus Stent
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date the device was implanted:

Is the device still implanted?


What medical condition prompted the use of the device?

Please describe any problems or injuries caused by the device:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Boston Scientific Taxus Stent


AddThis Social Bookmark Button

Boston Scientific Taxus Stent

The Boston Scientific Taxus Express Stent was approved in March 2004 and has made the company into the largest coronary stent manufacturer in the U.S.  The stent emits paclitaxel, a drug intended to inhibit restenosis caused by scar tissue growth.  The stent uses a proprietary polymer, Translute™, to control the release of the drug paclitaxel.  In late November 2006, a new meta analysis by the Cleveland Clinic of 14 studies of drug coated heart stents found that the incidence of blood clots with these newer devices is four to five times the incidence associated with the original metal stents which eluted no drugs.  Because of the increased risk of thrombosis and resulting heart attacks, patients with the paclitaxel-eluting Boston Scientific Taxus stent are required to take anti-clotting medications for six months or more.  If you or a loved one have a Taxus stent and have suffered clotting as a result, contact Parker & Waichman, LLP for a free legal case consultation.  Call 1-800-LAW-INFO (1-800-529-4636) or fill out the form at the right for legal assistance.

Taxus Stent Recalls
Boston Scientific Corp., the largest maker of heart stents, has had multiple voluntary recalls of its drug-coated Taxus devices because of defects in the delivery system. About 200 Taxus stents were recalled in July 2004. After identifying further problems, the company recalled 85,000 Taxus stents (both drug coated and bare metal types) later that month.  In August 2004, an additional 3,000 Taxus stents were recalled that had been manufacturered prior to the aforementioned recalls.  The catheter problems appear to have been caused when too much heat was applied during the laser welding stage in the manufacturing process, the company said.

If you or a loved one suffered injuries from a Boston Scientific Taxus stent, please fill out the form at the right for a free case evaluation by a qualified defective medical device attorney.
Boston Scientific Taxus StentRSS Feed

Recall for Boston Scientific Implantable Defibrillators

Mar 16, 2010 | Parker Waichman Alonso LLP
A massive recall is being issued for seven brands of Boston Scientific implantable heart defibrillators.  The recall is being issued because Boston Scientific has determined that it did not get approval from federal regulators for changes to its manufacturing processes. According to a Boston Scientific press release, the company is halting sales and retrieving field inventory of all its implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators...

Lawsuits Allege Medtronic, Other Firms Illegally Marketed Surgical Ablation Products

Jul 16, 2009 | Parker Waichman Alonso LLP
Medtronic Inc., St. Jude Medical Inc., AtriCure Inc. and Boston Scientific Corp. all allegedly paid kickbacks to doctors in order to convince them to use their surgical ablation products to treat the heart-rhythm defect called atrial fibrillation, according to lawsuits recently unsealed in Texas.   According to The Wall Street Journal, the lawsuits were filed by former employees of the companies.Allegations of kickbacks by medical device makers are nothing new.  For example, in...

FDA Approves Boston Scientific Stent Despite Earlier Problems

Oct 13, 2008 | Parker Waichman Alonso LLP
Late last week, Boston Scientific Corporation announced that U.S. health regulators approved the next-generation version of its widely used Taxus drug-coated stent.  Boston Scientifc plans to begin selling the stent in early November.Meanwhile, in March, Boston Scientific received an approvable letter from the Food and Drug Administration (FDA) for the stent, the Taxus Liberte.  Receiving an approvable letter indicates that certain conditions must be met before full FDA approval is...

Surgery Deemed More Effective Than Boston Scientifics Taxus Stent

Sep 2, 2008 | Parker Waichman Alonso LLP
Doctors are now reporting that Boston Scientific Corporation’s Taxus stent did not fare as well as bypass surgery in improving medical outcomes for the sickest patients with a build-up of fatty deposits in their arteries.  After one year, 12.1 percent of bypass patients had died, experienced a heart attack or stroke, or required repeat surgery versus the 17.8 percent of those patients who received a tube—known as a stent—to prop open a clogged artery.  The...

Efficacy of heart stents called into question

Mar 27, 2007 | Financial Times
A seven-year US study has called into question whether doctors are overusing heart stents, the blockbuster tiny wire mesh tubes used to prop open narrowing coronary arteries. The results of the study, called Courage, added more uncertainty to a stent market that recently has been thrown into flux over questions of safety, appropriate usage and new competition. This flux was also highlighted by a 7 per cent fall in the share price of Boston Scientific, a leading US stent maker, because new...

More Boston Scientific Taxus Stent News